Tim Lu’s gene-cir­cuit star Sen­ti signs up for a $645M dis­cov­ery al­liance with Roche sub Spark

Three months af­ter bring­ing in Bay­er and a group of new in­vestors in his first mega-round, Sen­ti Bio chief Tim Lu now has the first high-pro­file Big Phar­ma al­liance to help bur­nish his prospects for a cut­ting-edge break­through in gene ther­a­pies.

Spark Ther­a­peu­tics — which Roche ac­quired as its base camp in gene ther­a­py de­vel­op­ment — has turned to Sen­ti in a col­lab­o­ra­tion aimed at us­ing its syn­thet­ic gene cir­cuit tech in new pro­grams aimed at the CNS, eye and liv­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER